Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

April 03, 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

April 06, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

March 14, 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

RAPID-HF: Rate-Adaptive Pacing Doesn’t Help in HFpEF

News Conference News ACC 2023

RAPID-HF: Rate-Adaptive Pacing Doesn’t Help in HFpEF

March 05, 2023

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

April 08, 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

March 28, 2022

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

News Conference News ACC 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

May 16, 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

May 15, 2021

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

Final MOMENTUM 3 Results Secure Superiority Claim for HeartMate 3 LVAD

News Conference News ACC 2019

Final MOMENTUM 3 Results Secure Superiority Claim for HeartMate 3 LVAD

March 22, 2019

Newest HeartMate 3 LV Assist Device Slashes Thrombosis, Reoperation Rates in Advanced HF: MOMENTUM 3

News Conference News ACC 2018

Newest HeartMate 3 LV Assist Device Slashes Thrombosis, Reoperation Rates in Advanced HF: MOMENTUM 3

March 16, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.